ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

Kemas kini terakhir: 5 hari lalu, 9:45PM

72.88

0.53 (0.73%)

  • 1H 0.73%
  • 5H 0.07%
  • 1B 10.04%
  • 6B 10.04%
  • Tahun Ke Tarikh 10.63%
  • 1T -8.43%
  • 5T 38.45%
Penutupan Terdahulu 72.35
Buka 72.42
Jumlah Dagangan 2,454,022
Purata Dagangan (3B) 5,617,301
Modal Pasaran 225,959,329,792
Harga / Pendapatan (P/E TTM) 29.27
Harga / Pendapatan (P/E Ke hadapan) 15.85
Harga / Jualan (P/S) 4.04
Harga / Buku (P/B) 6.19
Julat 52 Minggu
61.24 (-15%) — 87.68 (20%)
Tarikh Pendapatan 29 Jul 2025
Hasil Dividen (DY TTM) 2.13%
Margin Keuntungan 13.01%
Margin Operasi (TTM) 22.72%
EPS Cair (TTM) 2.25
Pertumbuhan Hasil Suku Tahunan (YOY) 23.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 56.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 74.53%
Nisbah Semasa (MRQ) 0.930
Aliran Tunai Operasi (OCF TTM) 11.86 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 8.46 B
Pulangan Atas Aset (ROA TTM) 7.88%
Pulangan Atas Ekuiti (ROE TTM) 17.59%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menurun Bercampur
Drug Manufacturers - General (Global) Menurun Bercampur
Stok Astrazeneca PLC Bercampur Menaik

AISkor Stockmoo

1.1
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata 1.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AZN 226 B 2.13% 29.27 6.19
SNY 122 B 4.43% 17.53 1.46
AMGN 157 B 3.17% 26.31 25.15
GILD 124 B 3.13% 20.97 7.30
GRFS 6 B - 28.00 0.910
BIIB 17 B - 11.68 1.14

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Institusi 17.52%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
02 Jun 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
01 Jun 2025 Pengumuman IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
01 Jun 2025 Pengumuman Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
29 May 2025 Pengumuman Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
27 May 2025 Pengumuman Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
21 May 2025 Pengumuman AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
20 May 2025 Pengumuman From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
19 May 2025 Pengumuman Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
13 May 2025 Pengumuman AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
09 May 2025 Pengumuman IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
07 May 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
05 May 2025 Pengumuman Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?
02 May 2025 Pengumuman BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
29 Apr 2025 Pengumuman AstraZeneca's Q1 2025 Financial Results
28 Apr 2025 Pengumuman SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
23 Apr 2025 Pengumuman Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
21 Apr 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
17 Apr 2025 CNBC Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
31 Mar 2025 Pengumuman IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
31 Mar 2025 Pengumuman ​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
26 Mar 2025 Pengumuman Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
25 Mar 2025 Pengumuman New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
17 Mar 2025 Pengumuman IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
17 Mar 2025 Pengumuman EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
14 Mar 2025 Pengumuman AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
Papar semua
Hasil Dividen (DY TTM) 2.13%
Purata Hasil Dividen 5T 2.35%
Nisbah Pembayaran 66.00%
Jangkaan Pembayaran Dividen Seterusnya Sep 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
21 Feb 2025 06 Feb 2025 24 Mar 2025 1.05 Tunai
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 Tunai
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 Tunai
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 Tunai
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 Tunai
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 Tunai
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 Tunai
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 Tunai
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 Tunai
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 Tunai
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 Tunai
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 Tunai
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 Tunai
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 Tunai
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 Tunai
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 Tunai
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 Tunai
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 Tunai
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 Tunai
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 Tunai
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 Tunai
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 Tunai
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 Tunai
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 Tunai
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 Tunai
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 Tunai
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 Tunai
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 Tunai
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 Tunai
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 Tunai
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 Tunai
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 Tunai
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 Tunai
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 Tunai
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 Tunai
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 Tunai
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 Tunai
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 Tunai
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 Tunai
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 Tunai
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 Tunai
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.05 1 1.44
2024 1.49 2 2.27
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
Papar semua
73.7373.7372.3672.3671.0071.0069.6369.6368.2668.26May 28May 28May 29May 29May 30May 30Jun 2Jun 2Jun 3Jun 3Jun 4Jun 4Jun 5Jun 5Jun 6Jun 6

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
2.0002.0001.5001.5001.0001.0000.5000.5000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda